DK1442030T3 - Thiopen- og thiazolsulfonamider som antineoplastiske midler - Google Patents

Thiopen- og thiazolsulfonamider som antineoplastiske midler

Info

Publication number
DK1442030T3
DK1442030T3 DK02802117T DK02802117T DK1442030T3 DK 1442030 T3 DK1442030 T3 DK 1442030T3 DK 02802117 T DK02802117 T DK 02802117T DK 02802117 T DK02802117 T DK 02802117T DK 1442030 T3 DK1442030 T3 DK 1442030T3
Authority
DK
Denmark
Prior art keywords
thiopen
antineoplastic agents
thiazole sulfonamides
sulfonamides
thiazole
Prior art date
Application number
DK02802117T
Other languages
Danish (da)
English (en)
Inventor
Dios Alfonso De
Cora Sue Grossman
De Uralde Lopez
Jose Eduardo Lopez
Mary Margaret Mader
Chaun Shih
Philip Arthur Hipskind
Ho-Shen Lin
Karen Lynn Lobb
Michael Enrico Richett
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1442030T3 publication Critical patent/DK1442030T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/34Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK02802117T 2001-10-25 2002-10-15 Thiopen- og thiazolsulfonamider som antineoplastiske midler DK1442030T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35201201P 2001-10-25 2001-10-25

Publications (1)

Publication Number Publication Date
DK1442030T3 true DK1442030T3 (da) 2006-12-27

Family

ID=23383421

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02802117T DK1442030T3 (da) 2001-10-25 2002-10-15 Thiopen- og thiazolsulfonamider som antineoplastiske midler

Country Status (34)

Country Link
US (2) US7084170B2 (pt)
EP (1) EP1442030B1 (pt)
JP (1) JP4464681B2 (pt)
KR (1) KR100913471B1 (pt)
CN (1) CN1298709C (pt)
AR (1) AR037248A1 (pt)
AT (1) ATE338033T1 (pt)
AU (1) AU2002334817B2 (pt)
BR (1) BR0212386A (pt)
CA (1) CA2463300C (pt)
CY (1) CY1106247T1 (pt)
DE (1) DE60214413T2 (pt)
DK (1) DK1442030T3 (pt)
EA (1) EA006081B1 (pt)
EC (1) ECSP045078A (pt)
EG (1) EG26021A (pt)
ES (1) ES2269816T3 (pt)
HK (1) HK1068337A1 (pt)
HR (1) HRP20040371B1 (pt)
HU (1) HUP0401638A3 (pt)
IL (2) IL160851A0 (pt)
MX (1) MXPA04003886A (pt)
MY (1) MY130718A (pt)
NO (1) NO20041316L (pt)
NZ (1) NZ531136A (pt)
PE (1) PE20030574A1 (pt)
PL (1) PL208083B1 (pt)
PT (1) PT1442030E (pt)
SI (1) SI1442030T1 (pt)
SV (1) SV2004001367A (pt)
TW (1) TWI281916B (pt)
UA (1) UA75716C2 (pt)
WO (1) WO2003035629A1 (pt)
ZA (1) ZA200403089B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1401825E (pt) * 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
WO2003104218A1 (en) * 2002-06-06 2003-12-18 Smithkline Beecham Corporation Nf-:b inhibitors
ES2345438T3 (es) 2002-12-10 2010-09-23 Virochem Pharma Inc. Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
WO2006030941A1 (ja) * 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
AU2006217690B2 (en) * 2005-02-28 2012-03-15 Eisai R & D Management Co., Ltd. Novel use of sulfonamide compound in combination with angiogenesis inhibitor
WO2006090921A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物のリンパ球活性化抑制作用
AU2006217692A1 (en) 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Novel combinational use of sulfonamide compound
JP5030947B2 (ja) 2005-05-13 2012-09-19 ヴァイロケム・ファーマ・インコーポレーテッド フラビウイルス感染の治療及び予防のための化合物及び方法
US7208506B2 (en) * 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
US20100291592A1 (en) 2006-04-20 2010-11-18 Taro Semba Novel marker for sensitivity against sulfonamide compound
US7939532B2 (en) 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
KR20090086081A (ko) * 2006-11-15 2009-08-10 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 치료 또는 예방용 티오펜 유사체
CN101675033A (zh) 2007-05-16 2010-03-17 霍夫曼-拉罗奇有限公司 芳基吡啶基磺酰胺衍生物,它们的制备和作为药剂的应用
CN101899008B (zh) * 2010-05-20 2012-10-17 中国人民解放军第二军医大学 N-取代嘧啶磺酰基-取代苯甲酰胺类化合物及其制备药物的用途
CN103450149B (zh) * 2012-06-01 2015-10-14 中国科学院上海有机化学研究所 苯基噻吩磺酰胺类化合物及其制备方法和用途
JP6364967B2 (ja) * 2014-05-30 2018-08-01 東ソー株式会社 ジチエノベンゾジチオフェンの製造方法
CN106588868A (zh) * 2016-11-16 2017-04-26 武汉理工大学 一种2‑溴‑3‑噻吩甲酸中间体的合成方法
CN108558822B (zh) * 2018-06-01 2020-12-18 盐城锦明药业有限公司 N-((5-溴噻吩-2-基)磺酰基)-2,4-二氯苯甲酰胺的合成方法
CN110835345A (zh) * 2018-08-17 2020-02-25 中国科学院上海药物研究所 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
CN109265437A (zh) * 2018-10-19 2019-01-25 凯莱英医药集团(天津)股份有限公司 一种3-羟基噻吩-2-羧酸酯类化合物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA813332B (en) * 1980-06-21 1982-05-26 Pfizer Larvicides and isecticides
ZA915371B (en) * 1990-07-17 1993-03-31 Lilly Co Eli Antitumor compositions and methods of treatment
US5177074A (en) * 1991-03-26 1993-01-05 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5169860A (en) * 1992-03-13 1992-12-08 Eli Lilly And Company Antitumor compositions and methods of treatment
CA2260128A1 (en) * 1996-07-05 1998-01-15 William G. Rice Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
EP0929540A4 (en) * 1996-10-04 2001-12-12 Lilly Co Eli ANTI-TUMOR COMPOSITIONS AND THERAPEUTIC METHODS
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、

Also Published As

Publication number Publication date
TWI281916B (en) 2007-06-01
KR20040062583A (ko) 2004-07-07
HRP20040371B1 (en) 2012-07-31
DE60214413T2 (de) 2007-03-08
ES2269816T3 (es) 2007-04-01
US20060223871A1 (en) 2006-10-05
AU2002334817B2 (en) 2008-02-21
EG26021A (en) 2012-12-10
US7250430B2 (en) 2007-07-31
DE60214413D1 (de) 2006-10-12
EP1442030A1 (en) 2004-08-04
KR100913471B1 (ko) 2009-08-25
PT1442030E (pt) 2006-12-29
EP1442030B1 (en) 2006-08-30
BR0212386A (pt) 2004-07-27
PL208083B1 (pl) 2011-03-31
SI1442030T1 (sl) 2006-12-31
IL160851A (en) 2009-11-18
UA75716C2 (en) 2006-05-15
EA200400582A1 (ru) 2004-08-26
PE20030574A1 (es) 2003-07-03
EA006081B1 (ru) 2005-08-25
US20040198784A1 (en) 2004-10-07
HUP0401638A2 (hu) 2004-11-29
WO2003035629A1 (en) 2003-05-01
IL160851A0 (en) 2004-08-31
ATE338033T1 (de) 2006-09-15
CN1575286A (zh) 2005-02-02
ECSP045078A (es) 2004-06-28
CY1106247T1 (el) 2011-06-08
CA2463300C (en) 2011-07-19
JP4464681B2 (ja) 2010-05-19
NZ531136A (en) 2006-08-31
CN1298709C (zh) 2007-02-07
US7084170B2 (en) 2006-08-01
HUP0401638A3 (en) 2012-09-28
MXPA04003886A (es) 2004-07-08
SV2004001367A (es) 2004-02-24
AR037248A1 (es) 2004-11-03
HK1068337A1 (en) 2005-04-29
JP2005511547A (ja) 2005-04-28
MY130718A (en) 2007-07-31
CA2463300A1 (en) 2003-05-01
HRP20040371A2 (en) 2004-08-31
PL368234A1 (en) 2005-03-21
NO20041316L (no) 2004-03-30
ZA200403089B (en) 2005-04-22

Similar Documents

Publication Publication Date Title
DK1442030T3 (da) Thiopen- og thiazolsulfonamider som antineoplastiske midler
NO20035775L (no) 3-fluor-pyrrolidiner som anti-diabetesmidler
DK1414803T3 (da) Pyrazolylcarboxanilider som fungicider
DK1414438T3 (da) Antineoplastiske kombinationer
NO20041567L (no) 1,8-nafthyridinderivater som antidiabetiske midler
NO20034439D0 (no) Benzamidinderivater
NO20042955L (no) Substituerte fenylaftalener som estrogene midler
NO20033573L (no) Vandig viskoelastisk fluid
NO20026195D0 (no) Substituerte-triazolopyrimidiner som anticancer midler
ATE319451T1 (de) Tetrahydrochinolin-derivate
DK1456206T3 (da) Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
NO20034949L (no) Sulfonamider
DK1455779T3 (da) Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander
NO20043794L (no) Benzensulfonamidderivater som antipsykotiske midler
DE60224485D1 (de) Drehventil
DK1429607T3 (da) Delta-1-pyrroliner som pesticider
DE50207798D1 (de) Tensidmischungen
NO20040860L (no) Farmasoytisk sammensetning som innbefatter lumiracoxib
NO20035317L (no) Antineoplastiske kombinasjoner
DE60234592D1 (de) Wässrige zusammensetzung
NO20041819L (no) Diazacykloalakaner som oksytocinagonister
NO20033234L (no) Karotenoider som antihypertensjonsmidler
DK1263734T3 (da) 3-thiomethylpyrazoler som pesticider
ATE330603T1 (de) Benzothiazolderivaten